IP Verse

Fcrn Antagonists And Methods Of Use - EP3087095

The patent EP3087095 was granted to Argen X on Aug 7, 2019. The application was originally filed on Dec 23, 2014 under application number EP14827372A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3087095

ARGEN X
Application Number
EP14827372A
Filing Date
Dec 23, 2014
Status
Granted And Under Opposition
Jul 5, 2019
Grant Date
Aug 7, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFIMay 7, 2020MATHYS & SQUIREWITHDRAWN

Patent Citations (49) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004002587
DESCRIPTIONUS2004010124
DESCRIPTIONUS2004047862
DESCRIPTIONUS2004265321
DESCRIPTIONUS2009252729
DESCRIPTIONUS2011081345
DESCRIPTIONUS2011243966
DESCRIPTIONUS5326856
DESCRIPTIONUS5624821
DESCRIPTIONUS5648260
DESCRIPTIONUS5677425
DESCRIPTIONUS5869046
DESCRIPTIONUS5885573
DESCRIPTIONUS6121022
DESCRIPTIONUS6165745
DESCRIPTIONUS6194551
DESCRIPTIONUS6212022
DESCRIPTIONUS6277375
DESCRIPTIONUS6528624
DESCRIPTIONUS6737056
DESCRIPTIONUS6821505
DESCRIPTIONUS8021856
DESCRIPTIONUS8067232
DESCRIPTIONUS8101186
DESCRIPTIONUS8216805
DESCRIPTIONWO0042072
DESCRIPTIONWO0158957
DESCRIPTIONWO02060919
DESCRIPTIONWO0206919
DESCRIPTIONWO0243658
DESCRIPTIONWO2004016750
DESCRIPTIONWO2004029207
DESCRIPTIONWO2004035752
DESCRIPTIONWO2004063351
DESCRIPTIONWO2004099249
DESCRIPTIONWO2005040217
DESCRIPTIONWO9429351
DESCRIPTIONWO9958572
INTERNATIONAL-SEARCH-REPORTUS6277375
INTERNATIONAL-SEARCH-REPORTWO02060919
INTERNATIONAL-SEARCH-REPORTWO2006130834
INTERNATIONAL-SEARCH-REPORTWO2009100105
INTERNATIONAL-SEARCH-REPORTWO2009131702
INTERNATIONAL-SEARCH-REPORTWO2010014909
INTERNATIONAL-SEARCH-REPORTWO2010106180
INTERNATIONAL-SEARCH-REPORTWO2013074598
OPPOSITIONEP1896503
OPPOSITIONWO2006130834
OPPOSITIONWO2013074598

Non-Patent Literature (NPL) Citations (59) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALEGRE ET AL., TRANSPLANTATION, (1994), vol. 57, pages 1537 - 1543-
DESCRIPTION- ANDERSEN ET AL., NAT COMMUN., (2012), vol. 3, page 610-
DESCRIPTION- ARMOUR ET AL., EUR J IMMUNOL, (1999), vol. 29, pages 2613 - 2624-
DESCRIPTION- CHAUDHURY ET AL., J EXP MED., (2003), vol. 197, no. 3, pages 315 - 22-
DESCRIPTION- CLARKSON ET AL., NEJM, (2013), vol. 314, no. 9, pages 1236 - 1239-
DESCRIPTION- DUNCAN ET AL., NATURE, (1988), vol. 332, pages 563 - 564-
DESCRIPTION- EDELMAN, G.M. ET AL., PROC. NATL. ACAD. USA, (1969), vol. 63, pages 78 - 85-
DESCRIPTION- GHETIE ET AL., NAT. BIOTECH., vol. 15, pages 637 - 40-
DESCRIPTION- HUTCHINS ET AL., PROC NATL. ACAD SCI USA, (1995), vol. 92, pages 11980 - 11984-
DESCRIPTION- IDUSOGIE ET AL., J. IMMUNOL., (2000), vol. 164, pages 4178 - 4184-
DESCRIPTION- IDUSOGIE ET AL., J. IMMUNOL., (2001), vol. 166, pages 2571 - 2575-
DESCRIPTION- JEFFERIS ET AL., IMMUNOL LETT., (1995), vol. 44, pages 111 - 117-
DESCRIPTION- JEFFERIS ET AL., IMMUNOL LETT., (1996), vol. 54, pages 101 - 104-
DESCRIPTION- JEFFERIS ET AL., IMMUNOL LETT., (2002), vol. 82, pages 57 - 65-
DESCRIPTION- JUNGHANS; ANDERSON, PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, page 5512-
DESCRIPTION- JUNGHANS, IMMUNOLOGIC RESEARCH, (1997), vol. 16, no. 1, page 29-
DESCRIPTION- LUND ET AL., FASEB J., (1995), vol. 9, pages 115 - 119-
DESCRIPTION- LUND ET AL., J. IMMUNOL., (1991), vol. 147, pages 2657 - 2662-
DESCRIPTION- LUND ET AL., J. IMMUNOL., (1996), vol. 157, pages 4963 - 4969-
DESCRIPTION- LUND ET AL., MOL. IMMUNOL., (1992), vol. 29, pages 53 - 59-
DESCRIPTION- "Mammalian Expression Vectors", RIDGWAY, A. A. G., Vectors, BUTTERWORTHS, BOSTON, MASS., (1988), pages 470 - 472-
DESCRIPTION- NIESWANDT ET AL., BLOOD, (1999), vol. 94, pages 684 - 93-
DESCRIPTION- OSHIMA ET AL., INT IMMUNOL, (1998), vol. 10, no. 4, pages 517 - 26-
DESCRIPTION- PATEL ET AL., J IMMUNOL, (2011), vol. 187, no. 2, pages 1015 - 22-
DESCRIPTION- PRESTA ET AL., BIOCHEM SOC TRANS., (2002), vol. 30, pages 487 - 490-
DESCRIPTION- REDDY ET AL., J. IMMUNOL., (2000), vol. 164, pages 1925 - 1933-
DESCRIPTION- ROOPENIAN ET AL., J. IMMUNOLOGY, (2003), vol. 170, page 3528-
DESCRIPTION- ROUX ET AL., J. IMMUNOL., (1998), vol. 161, page 4083-
DESCRIPTION- SHIELDS ET AL., J BIOL. CHEM., (2001), vol. 276, pages 6591 - 6604-
DESCRIPTION- VACCARO ET AL., NATURE BIOTECH, (1997), vol. 23, no. 9, pages 1283 - 1288-
DESCRIPTION- XU ET AL., CELL IMMUNOL., (2000), vol. 200, pages 16 - 26-
INTERNATIONAL-SEARCH-REPORT- CARLOS VACCARO ET AL, "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels", NATURE BIOTECHNOLOGY, (20051001), vol. 23, no. 10, doi:10.1038/nbt1143, ISSN 1087-0156, pages 1283 - 1288, XP055049342 [X] 3-9,20-27,41-44 * the whole document *
OPPOSITION- arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders, (20140424), URL: https://www.argenx.com/en- GB /news- internal/argen-x-advances-argx-113-into-preclinical-development-for- autoi m m une-di sorders/60, XP055698696-
OPPOSITION- "arGEN-X Announces Positive Preclinical Results for ARGX-113", (20140819), URL: https://www.argenx.com/en-GB/news-internal/argen-x-announces-positive-preclinical-results-for-argx-113/39, XP055698696-
OPPOSITION- DALL'ACQUA et al., "Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences", J. Immunol., (20021101), vol. 169, no. 9, pages 5171 - 5180, XP002268422-
OPPOSITION- DIMITROV, "Engineered CH 2 domains (nanoantibodies", MAbs., (20090100), vol. 1, no. 1, pages 26 - 28, XP002596414-
OPPOSITION- PUTNAM et al., "Proteins in multiple myeloma. VIII. Biosynthesis of abnormal proteins", J. Biol. Chem., (19580401), vol. 231, no. 2, pages 671 - 684, XP055698695-
OPPOSITION- BRYCH et al., "Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation", J. Pharm. Sci., (20100200), vol. 99, no. 2, doi:10.1002/jps.21868, pages 764 - 781, XP055410648
OPPOSITION- DEBRE et al., "Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura", Lancet, (19931016), vol. 342, doi:10.1016/0140-6736(93)92000-J, pages 945 - 949, XP055311761
OPPOSITION- WARD et al., "Multitasking by exploitation of intracellular transport functions: the many faces of FcRn", Adv. Immunol., (20090000), vol. 103, doi:10.1016/S0065-2776(09)03004-1, pages 77 - 115, XP008142597
OPPOSITION- BRUHNS et al., "Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease", Immunity, (20030400), vol. 18, no. 4, pages 573 - 581, XP055698693
OPPOSITION- WEINER et al., "Tunable antibodies", Nat. Biotechnol., (20050500), vol. 23, no. 5, doi:10.1038/nbt0505-556, pages 556 - 557, XP002720691
OPPOSITION- BLUMBERG et al., "Antibodies in the breakdown lane", Nat Biotechnol., (20051001), vol. 23, no. 10, pages 1232 - 1234, XP055698690
OPPOSITION- VACCARO et al., "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels", Nat Biotechnol., (20051000), vol. 23, no. 10, doi:10.1038/nbt1143, pages 1283 - 1288, XP055049342
OPPOSITION- CARTER P. J., "Potent antibody therapeutics by design", Nat. Rev. Immunol., (20060500), vol. 6, no. 5, doi:10.1038/nri1837, pages 343 - 357, XP007901440
OPPOSITION- SCHWAB et al., "Intravenous immunoglobulin therapy: how does IgG modulate the immune system?", Nat. Rev. Immunol., (20130300), vol. 13, no. 3, doi:10.1038/nri3401, pages 176 - 189, XP055234901
OPPOSITION- VACCARO et al., "Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies", Proc Natl Acad Sci USA, (20061205), vol. 103, no. 49, doi:10.1073/PNAS.0606304103, pages 18709 - 18714, XP002518923
OPPOSITION- SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and design of IgG1 variants with improved binding to the FcyR", J. Biol. Chem., (20010302), vol. 276, no. 9, pages 6591 - 6604, XP002638208
OPPOSITION- GOH et al., "Impact of host cell line choice on glycan profile", Crit. Rev. Biotechnol., (20180900), vol. 38, no. 6, doi:10.1080/07388551.2017.1416577, pages 851 - 867, XP055617047
OPPOSITION- GAN et al., "Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery", Traffic, (20090500), vol. 10, no. 5, pages 600 - 614, XP055698691
OPPOSITION- KANEKO et al., "Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation", Science, (20060804), vol. 313, no. 5787, doi:10.1126/science.1129594, pages 670 - 673, XP008076047
OPPOSITION- ANTHONY et al., "Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc", Science, (20080418), vol. 320, no. 5874, pages 373 - 376, XP002538506
OPPOSITION- SAMUELSSON et al., "Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor", Science, (20010119), vol. 291, no. 5503, doi:10.1126/science.291.5503.484, pages 484 - 486, XP002430254
OPPOSITION- ULTRICHTS et al., "Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans", J. Clin. Invest., (20181001), vol. 128, no. 10, doi:10.1172/JCI97911, pages 4372 - 4386, XP055552033
OPPOSITION- PYZIK et al., "The neonatal Fc Receptor (FcRn): A misnomer?", Front. Immunol., (20190710), vol. 10, doi:10.3389/fimmu.2019.01540, page 1540, XP055655948
OPPOSITION- PATEL et al., "Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model", J. Immunol., (20110715), vol. 187, no. 2, doi:10.4049/jimmunol.1003780, pages 1015 - 1022, XP055292443
OPPOSITION- GOMEZ-GUERRERO et al., "Administration of IgG Fc fragments prevents glomerular injury in experimental immune complex nephritis", J. Immunol., (20000215), vol. 164, no. 4, pages 2092 - 2101, XP055698692
OPPOSITION- JEFFERIS, "Human immunoglobulin allotypes: possible implications for immunogenicity", MAbs, (20090700), vol. 1, no. 4, doi:10.4161/mabs.1.4.9122, pages 332 - 338, XP002674897
OPPOSITION- CHALLA et al., "Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis", MAbs, vol. 5, no. 5, doi:10.4161/mabs.25439, pages 655 - 659, XP055292468

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents